The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
- Author:
Sung-Yong KIM
1
;
Sung Hwa BAE
;
Soo-Mee BANG
;
Ki-Seong EOM
;
Junshik HONG
;
Seongsoo JANG
;
Chul Won JUNG
;
Hee-Jin KIM
;
Ho Young KIM
;
Min Kyoung KIM
;
Soo-Jeong KIM
;
Yeung-Chul MUN
;
Seung-Hyun NAM
;
Jinny PARK
;
Jong-Ho WON
;
Chul Won CHOI
Author Information
- Publication Type:REVIEW
- From:The Korean Journal of Internal Medicine 2021;36(1):45-62
- CountryRepublic of Korea
- Language:English
- Abstract: In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional somatic mutations have a clinical impact on the prognosis of patients harboring these genetic abnormalities. Treatment strategies have also advanced with the introduction of JAK inhibitors, one of which has been approved for the treatment of patients with myelofibrosis and those with hydroxyurea-resistant or intolerant polycythemia vera. Recently developed drugs aim to elicit hematologic responses, as well as symptomatic and molecular responses, and the response criteria were refined accordingly. Based on these changes, we have revised the guidelines and present the diagnosis, treatment, and risk stratification of MPNs encountered in Korea.
